Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 February 2019 | Story Zama Feni | Photo Charl Devenish
Disease Control and Prevention InStory
From left, seated: Dr Mathew Esona, CDC delegate; Dr Michael Bowen, CDC delegate; Dr Martin Nyaga, lead Researcher at the UFS-NGS Unit; standing: Mojalefa Buti, Office of the Vice-Dean, UFS Faculty of Health Sciences; Dr Glen Tylor, Senior Director, Directorate Research Development; Cornelius Hagenmeier, Director, Office for International Affairs; and Dr Saheed Sabiu, Postdoctoral Research Fellow in the Faculty of Natural and Agricultural Sciences.

In pursuit of efforts to advance research on viruses and disease control, the United States-based Centre for Disease Control and Prevention (CDC) has made a commitment to enhance the University of the Free State (UFS) Next Generation Sequencing (NGS) Unit’s data collection systems and further empower its staff and students.

UFS and US guests explore areas of mutual; cooperation

During a visit to the university in early December last year CDC delegation, Dr Michael Bowen and Dr Mathew Esona, a meeting was held with the lead Researcher at the UFS-NGS Unit, Dr Martin Nyaga; Senior Director of the UFS Directorate Research Development, Dr Glen Tylor; Director of UFS Office for International Affairs, Cornelius Hagenmeier; and Dr Saheed Sabiu Postdoctoral Research Fellow in the Faculty of Natural and Agriculture Sciences. It was in this meeting that areas of mutual collaboration and engagement between the two institutions which include technology transfer, funding and wet and dry laboratory quality control and capacity development were identified.

The UFS-NGS Unit, established in 2016, enjoys longstanding networking and collaborative ventures with renowned researchers in Africa, the USA, and Europe – which in return, have contributed immensely to the research activities of the university as a whole.

Dr Nyaga said in an effort to advance genomics research in the NGS Unit, the visitors have committed themselves to initiate and further enhance capacity development for the unit’s staff and students.

US guests impressed with advanced equipment at UFS

The CDC delegation were intrigued that the UFS also operates a Miseq Illumina platform like the one used at their enteric-viruses laboratory. It could thus be in line to assist in developing exclusive pipelines for the analysis of NGS data generated by the UFS-NGS Unit.

This is a personal sequencing system, which is a powerful state-of-the-art next-generation sequencer. It uses sequencing-by-synthesis technology capable of sequencing up to 15GB of high-quality filtered bases per run, with up to 600 base-pair read lengths. This allows the assembly of small genomes or the detection of target variants with unmatched accuracy, especially within homo-polymer regions.

UFS and CDC engagements still on

Further engagements about the identified areas of collaboration are ongoing between Hagenmeier, Dr Bowen, and Dr Nyaga, who are currently working on appropriate mechanisms to enact the envisaged collaboration between the two institutions.

The NGS Unit received research awards from the World Health Organisation, South African Medical Research Council, Poliomyelitis Research Foundation, and the National Research Foundation for different aspects of genomics research, and more recently from the Bill and Melinda Gates Foundation for the Enteric Viruses Genome Initiative, involving four African countries (South Africa, Ghana, Malawi, and Cameroon).

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept